Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ladinin-1 (LAD1) is a collagenous anchoring filament protein primarily localized to basement membranes, where it plays a vital role in the integrity and cohesion of tissue boundaries, particularly at the dermal-epidermal junction[1][4][5][6]. It ensures stable adhesion between epithelial layers and the mesenchyme. LAD1 is dynamically regulated in response to various physiological and pathological signals, including glucocorticoid receptor signaling. Pathologically, LAD1 is notable as a major autoantigen in linear IgA bullous dermatosis, an autoimmune blistering skin disorder[1][4]. Additionally, its dysregulation is implicated in tumor proliferation, migration, and metastasis, particularly in epithelial cancers such as oral squamous cell carcinoma, prostate cancer, and laryngeal squamous cell carcinoma[1][2]. LAD1 is considered a potential prognostic biomarker and a putative therapeutic target due to its dual role as a structural protein and immunologically reactive molecule[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ladinin-1 (LAD1).